Why did SPL rise 9.8% on 16 Apr 2026?
Starpharma · Pharmaceuticals, Biotechnology & Life Sciences
What moved it
No specific company announcement found; the stock's rally appears to be part of a broader uptrend and technical breakout, as highlighted by multiple market analysis articles.
How we got there
The news around the date mentions Starpharma in context of its 580% year gain and ASX technical scans, but no specific catalyst like earnings or contracts is reported. The large price move and volume suggest investor momentum driven by technical factors and broader market attention, rather than a single news event.
The evidence
In the news
DGL Group to Progress Strategic Projects After Posting Lower H1 FY26 Earnings
smallcaps.com.au · 15 Apr 2026
Starpharma (ASX:SPL) Jumps Over 580% in a Year: What’s Behind the Rally?
Kalkine · 16 Apr 2026
ChartWatch ASX Scans: Evolution Mining, Bannerman Energy, Sunrise Energy Metals, Cochlear, Racura Oncology, Starpharma
Market Index · 16 Apr 2026
ASX 200 ChartWatch: Uptrends Surge While Laggards Slip
Kalkine Media · 16 Apr 2026
8 articles read; the newest from each outlet is shown. Headlines link to the publisher.
Held by no ETF
Not currently held by any ETF we track.
Keep going
More moves in SPL
- −8.6%1 Oct 2026A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
- +4.3%13 Aug 2026Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
- −5.4%12 Aug 2026Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.